Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dr. Lal PathLabsNSE:LALPATHLAB -0.21%93 Pretax Margin % is 28.67% as of Jun. 2026, which is 17% above its 10-year median of 24.47. GuruFocus rates NSE:LALPATHLAB with a GF Score™ of 93/100 and a GF Value™ of ₹1,735.83 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 201 Medical Diagnostics & Research companies, Dr. Lal PathLabs ranks better than 93.03% on this metric.
The historical rank and industry rank for Dr. Lal PathLabs's Pretax Margin % or its related term are showing as below:
NSE:LALPATHLAB'
s Pretax Margin % Range Over the Past 10 Years
Min: 17.05 Med: 24.47 Max: 25.96
Current: 24.79
NSE:LALPATHLAB's Pretax Margin % is ranked better than 93.03% of 201
companies
in the Medical Diagnostics & Research industry
Industry Median: -4.31
vs NSE:LALPATHLAB: 24.79
Dr. Lal PathLabs (NSE:LALPATHLAB) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Dr. Lal PathLabs Pretax Margin % Related Terms
Dr. Lal PathLabs Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Dr. Lal PathLabs's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:LALPATHLAB vs TMO, DHR, IDXX: Pretax Margin % Comparison
For the Diagnostics & Research subindustry, Dr. Lal PathLabs's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dr. Lal PathLabs Pretax Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Dr. Lal PathLabs's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Dr. Lal PathLabs's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dr. Lal PathLabs (NSE:LALPATHLAB) has a Pretax Margin % of 28.67% as of Jun. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Dr. Lal PathLabs and its competitors. This is 17% above median its historical median of 24.47. Over the past decade, Dr. Lal PathLabs' Pretax Margin % has ranged from 17.05 to 25.96. According to the industry distribution chart, Dr. Lal PathLabs ranks #14 out of 201 companies in the Medical Diagnostics & Research industry, placing it in the top 7%.
Is Dr. Lal PathLabs' Pretax Margin % too high?
Dr. Lal PathLabs' current Pretax Margin % of 28.67% is 17% above median its 10-year median of 24.47. Over the past 10 years, this metric has ranged from a low of 17.05 to a high of 25.96. Based on the distribution chart, Dr. Lal PathLabs ranks #14 out of 201 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Dr. Lal PathLabs has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dr. Lal PathLabs' Pretax Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Dr. Lal PathLabs ranks #14 out of 201 companies for Pretax Margin %. This places Dr. Lal PathLabs in the top 7% of its industry — outperforming the majority of peers. Historically, Dr. Lal PathLabs' own Pretax Margin % has ranged from 17.05 to 25.96 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Diagnostics & Research company?
A good Pretax Margin % depends on the Medical Diagnostics & Research industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Dr. Lal PathLabs and its competitors. Dr. Lal PathLabs's current Pretax Margin % is 28.67%, which is 17% above median its own 10-year median of 24.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dr. Lal PathLabs stock overvalued right now?
Based on GuruFocus' analysis, Dr. Lal PathLabs (NSE:LALPATHLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,735.83, compared to a current price of ₹1,949.90 — trading 12.3% above its estimated fair value. The current Pretax Margin % is 28.67%, which is 17% above median its 10-year median of 24.47. Dr. Lal PathLabs' overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Dr. Lal PathLabs (NSE:LALPATHLAB), the current Pretax Margin % is 28.67% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dr. Lal PathLabs (NSE:LALPATHLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Dr. Lal PathLabs stock appears to be overvalued.
The current stock price of ₹1,949.90 is trading 12.3% above its estimated GF Value™ of ₹1,735.83.
GuruFocus considers Dr. Lal PathLabs to be Modestly Overvalued.
Key valuation signals for NSE:LALPATHLAB:
Pretax Margin %: 28.67% (17% above median its 10-year median of 24.47)
GF Value™: ₹1,735.83 vs. price of ₹1,949.90 (12.3% above fair value)
No single metric tells the full story. See the NSE:LALPATHLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dr. Lal PathLabs Ltd is a pathology lab based in India. It is involved in providing diagnostic services and other healthcare tests in the areas of pathology and radiology. The company operates laboratories for carrying out pathological diagnostic services in various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, and other pathological and radiological investigations. Its diagnostic services assist in preventing, monitoring, and treating diseases and improving health conditions. The company has business operations in India and other countries, of which maximum revenue is generated within India.
93GF Score
Get the complete analysis for NSE:LALPATHLAB
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:LALPATHLAB has been successfully added to your 
